Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06862856 · ClinicalTrials.gov registry record
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
A clinical trial of Prostate Cancer (Adenocarcinoma) and Prostate Specific Antigen, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT06862856: Recruiting study of Prostate Cancer (Adenocarcinoma) and Prostate Specific Antigen, sponsored by Massachusetts General Hospital.
NCT06862856 is a study of Prostate Cancer (Adenocarcinoma) and Prostate Specific Antigen that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 126-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (60% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06862856, a study of Prostate Cancer (Adenocarcinoma) and Prostate Specific Antigen, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.
Primary Outcome
The detection rate is defined as the percentage of all patients scanned who have at least one positive lesion (localized correspondence between flotufolastat F 18 PET/CT imaging and the reference standard) regardless of coexisting false positive findings.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Positron Emission Tomography (PET)
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2026-12-01 |
What NCT06862856 shows while recruiting
NCT06862856 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 126-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (60% lower).
The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which Positron Emission Tomography (PET) is the first listed.
NCT06862856 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06862856 about?
NCT06862856 is a clinical study titled "Flotufolastat F 18 PET in Men With Very Low PSA Recurrence". The purpose of this study is to assess detection rate of flotufolastat F 18 positron emission tomography (PET) for low prostate specific antigen (PSA) recurrence of prostate cancer (PC) following radical prostatectomy.
What is the current status of trial NCT06862856?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-05-20. Estimated completion is 2026-12-01.
What conditions does trial NCT06862856 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen.
What interventions are being tested in trial NCT06862856?
The interventions under investigation include: Positron Emission Tomography (PET) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06862856?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06862856 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06862856's enrollment target sits among peer trials
50 10th of 13 higher than 4 of 13 other Prostate Cancer (Adenocarcinoma) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer (Adenocarcinoma) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI